C-PVYUNeuroAge Therapeutics
AI cognitive testing, multi-modal diagnostics, brain aging biomarkers
discoverydiscovering
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PVYU
C-PVYUC-PVYUAI cognitive testing, multi-modal diagnostics, brain aging biomarkers
0-100 chain-logic scale · 15 dimensions · scored on public evidence
NeuroAge Therapeutics AI cognitive testing, multi-modal diagnostics, brain aging biomarkers
NeuroAge offers multi-modal testing for brain aging and dementia risk, including cognitive testing, MRI analysis, genetics, blood biomarkers, and coaching. Its NeuroGames platform provides cognitive testing, personalized insights, tracking, and science-backed brain training. The company says its products are designed for early detection and personalized recommendations for preventive brain health.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
NeuroAge Therapeutics — Far from goals · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (2 programs at undisclosed).…
Source: Deterministic